Sign in or create an account to add this stock to your watchlist.
About Ligand Pharmaceuticals (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500
Debt
Debt-to-Equity Ratio0.03
Current Ratio1.41
Quick Ratio1.37
Price-To-Earnings
Trailing P/E Ratio74.31
Forward P/E Ratio43.97
P/E Growth1.73
Sales & Book Value
Annual Sales$141.10 million
Price / Sales28.74
Cash Flow$3.8366 per share
Price / Cash49.62
Book Value$22.58 per share
Price / Book8.43
Profitability
EPS (Most Recent Fiscal Year)$2.57
Net Income$12.55 million
Net Margins31.40%
Return on Equity19.10%
Return on Assets11.69%
Miscellaneous
Employees39
Outstanding Shares21,300,000
Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions
What is Ligand Pharmaceuticals' stock symbol?
Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals' earnings last quarter?
Ligand Pharmaceuticals (NASDAQ:LGND) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported $1.55 EPS for the quarter, topping the Zacks' consensus estimate of $1.29 by $0.26. The biotechnology company had revenue of $56.16 million for the quarter, compared to analysts' expectations of $43.02 million. Ligand Pharmaceuticals had a return on equity of 19.10% and a net margin of 31.40%. The firm's revenue was up 91.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.57 EPS. View Ligand Pharmaceuticals' Earnings History.
When is Ligand Pharmaceuticals' next earnings date?
What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?
Ligand Pharmaceuticals updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.56. The company issued revenue guidance of $184 million, compared to the consensus revenue estimate of $186.50 million.
What price target have analysts set for LGND?
5 analysts have issued 12 month price targets for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $200.00. On average, they expect Ligand Pharmaceuticals' share price to reach $159.00 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.
What are Wall Street analysts saying about Ligand Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ligand’s earnings and revenues beat estimates in fourth-quarter 2017. The company’s captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Additionally, the company’s entry into the Medical Devices Segment with the buyout of multiple programs owned by CorMatrix is encouraging. Shares of Ligand have outperformed the broader industry in the past year. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to these two products could leave a substantial impact. Moreover, Ligand’s dependence on a single supplier to obtain Captisol is concerning." (2/28/2018)
- 2. HC Wainwright analysts commented, "Kyprolis Beats; Recent and Anticipated Label Expansions Represent Revenue Inflection Points Kyprolis quickly approaching blockbuster status. Yesterday, partner Amgen (AMGN; not rated) announced 4Q17 and 2017 Kyprolis revenue of $227M and $835M, respectively, compared with our estimates of $220M (consensus $225M) and $828M. As Kyprolis approaches blockbuster status, considering certain factors we think should be able to easily push it over the edge, and they include: 1) recent FDA approval of sNDA based on ENDEAVOR overall survival data; 2) recent CHMP positive opinion to include updated overall survival from ENDEAVOR on label this year in the E.U.; and 3) recent submission of sNDA to FDA and a variation to the marketing authorization to the EMA, both based on the overall survival benefit from the ASPIRE study (actions expected this year). Upcoming milestones and key programs underway: 2018 initial visibility from recent launch of Baxdela for serious skin infections." (2/2/2018)
Who are some of Ligand Pharmaceuticals' key competitors?
Some companies that are related to Ligand Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Sarepta Therapeutics (SRPT).
Who are Ligand Pharmaceuticals' key executives?
Ligand Pharmaceuticals' management team includes the folowing people:
- Mr. John L. Higgins, CEO & Exec. Director (Age 48)
- Mr. Matthew W. Foehr, Pres & COO (Age 45)
- Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 43)
- Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 49)
- Ms. Audrey Warfield-Graham, VP of HR
Has Ligand Pharmaceuticals been receiving favorable news coverage?
Headlines about LGND stock have trended somewhat positive on Thursday, according to Accern. The research firm rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Ligand Pharmaceuticals' major shareholders?
Ligand Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.22%), Summit Trail Advisors LLC (9.15%), Knott David M (2.61%), Victory Capital Management Inc. (2.41%), Cardinal Capital Management LLC CT (2.06%) and Eagle Asset Management Inc. (2.06%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.
Which institutional investors are selling Ligand Pharmaceuticals stock?
LGND stock was sold by a variety of institutional investors in the last quarter, including Cardinal Capital Management LLC CT, Knott David M, Oak Ridge Investments LLC, Russell Investments Group Ltd., Elk Creek Partners LLC, Eaton Vance Management, Next Century Growth Investors LLC and Mesirow Financial Investment Management Equity Management. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba and Todd C Davis. View Insider Buying and Selling for Ligand Pharmaceuticals.
Which institutional investors are buying Ligand Pharmaceuticals stock?
LGND stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, UBS Group AG, Matarin Capital Management LLC, Penserra Capital Management LLC, OppenheimerFunds Inc., King Luther Capital Management Corp, BlackRock Inc. and Chicago Equity Partners LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.
How do I buy shares of Ligand Pharmaceuticals?
Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals' stock price today?
One share of LGND stock can currently be purchased for approximately $190.76.
How big of a company is Ligand Pharmaceuticals?
Ligand Pharmaceuticals has a market capitalization of $3.99 billion and generates $141.10 million in revenue each year. The biotechnology company earns $12.55 million in net income (profit) each year or $2.57 on an earnings per share basis. Ligand Pharmaceuticals employs 39 workers across the globe.
How can I contact Ligand Pharmaceuticals?
Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]
MarketBeat Community Rating for Ligand Pharmaceuticals (LGND)
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe LGND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LGND will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Ligand Pharmaceuticals in the last 12 months. Their average twelve-month price target is $159.00, suggesting that the stock has a possible downside of 16.48%. The high price target for LGND is $200.00 and the low price target for LGND is $105.00. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.60 | 2.60 | 2.60 | 2.60 |
| Ratings Breakdown: | 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $159.00 | $159.00 | $152.00 | $145.80 |
| Price Target Upside: | 16.48% downside | 4.14% downside | 2.78% downside | 12.13% upside |
Ligand Pharmaceuticals (NASDAQ:LGND) Consensus Price Target History
Ligand Pharmaceuticals (NASDAQ:LGND) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Ligand Pharmaceuticals (NASDAQ:LGND) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.30%
Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | John L Higgins | CEO | Sell | 12,405 | $179.97 | $2,232,527.85 | 119,824 |  |
| 5/10/2018 | Matthew W Foehr | Insider | Sell | 8,881 | $167.63 | $1,488,722.03 | 110,082 | |
| 4/2/2018 | John W Kozarich | Director | Sell | 2,500 | $160.43 | $401,075.00 | | |
| 3/12/2018 | Stephen L Sabba | Director | Sell | 622 | $180.73 | $112,414.06 | 26,363 | |
| 3/9/2018 | Jason Aryeh | Director | Sell | 7,500 | $175.73 | $1,317,975.00 | 58,625 | |
| 3/5/2018 | John L Lamattina | Director | Sell | 3,335 | $160.90 | $536,601.50 | 24,291 | |
| 2/27/2018 | Todd C Davis | Director | Sell | 17,170 | $152.37 | $2,616,192.90 | 65,898 | |
| 2/23/2018 | Jason Aryeh | Director | Sell | 3,417 | $155.00 | $529,635.00 | 58,625 | |
| 2/23/2018 | Matthew W Foehr | COO | Sell | 5,444 | $152.98 | $832,823.12 | 95,835 | |
| 2/15/2018 | John L Higgins | CEO | Sell | 9,000 | $157.03 | $1,413,270.00 | 102,700 | |
| 1/24/2018 | John L Higgins | CEO | Sell | 22,500 | $165.00 | $3,712,500.00 | 111,700 | |
| 1/19/2018 | John L Higgins | CEO | Sell | 28,099 | $153.70 | $4,318,816.30 | 162,299 | |
| 1/10/2018 | John W Kozarich | Director | Sell | 2,500 | $145.00 | $362,500.00 | 33,149 | |
| 12/20/2017 | Stephen L Sabba | Director | Sell | 925 | $137.25 | $126,956.25 | 26,985 | |
| 11/17/2017 | Matthew E Korenberg | VP | Sell | 6,559 | $142.63 | $935,510.17 | 8,147 | |
| 11/16/2017 | John L Higgins | CEO | Sell | 5,269 | $142.53 | $750,990.57 | 143,542 | |
| 11/16/2017 | John W Kozarich | Director | Sell | 5,000 | $141.71 | $708,550.00 | 35,649 | |
| 9/5/2017 | John L Higgins | CEO | Sell | 5,000 | $130.00 | $650,000.00 | 144,171 | |
| 8/23/2017 | Jason Aryeh | Director | Sell | 2,000 | $127.99 | $255,980.00 | 59,625 | |
| 8/9/2017 | Charles S Berkman | VP | Sell | 18,625 | $126.96 | $2,364,630.00 | 24,423 | |
| 8/9/2017 | Matthew W Foehr | Insider | Sell | 6,100 | $127.51 | $777,811.00 | 101,020 | |
| 8/8/2017 | John L Higgins | CEO | Sell | 5,483 | $125.00 | $685,375.00 | 144,654 | |
| 6/21/2017 | John L Higgins | CEO | Sell | 4,666 | $120.00 | $559,920.00 | 143,837 | |
| 6/9/2017 | John L Higgins | CEO | Sell | 12,000 | $114.87 | $1,378,440.00 | 151,171 | |
| 5/12/2017 | Jason Aryeh | Director | Sell | 37,247 | $110.76 | $4,125,477.72 | 58,959 | |
| 5/12/2017 | Matthew W Foehr | Insider | Sell | 5,621 | $112.20 | $630,676.20 | 98,341 | |
| 3/20/2017 | John L Higgins | CEO | Sell | 4,000 | $109.10 | $436,400.00 | 139,171 | |
| 3/2/2017 | Matthew W Foehr | Insider | Sell | 6,879 | $103.39 | $711,219.81 | 97,599 | |
| 2/28/2017 | Jason Aryeh | Director | Sell | 32,000 | $106.35 | $3,403,200.00 | 58,959 | |
| 11/25/2016 | Jason Aryeh | Director | Sell | 18,479 | $107.31 | $1,982,981.49 | 58,959 | |
| 11/18/2016 | Jason Aryeh | Director | Sell | 6,330 | $105.28 | $666,422.40 | 58,959 | |
| 9/22/2016 | John L Higgins | CEO | Sell | 3,000 | $117.34 | $352,020.00 | 122,664 | |
| 9/7/2016 | John W Kozarich | Director | Sell | 1,000 | $115.00 | $115,000.00 | 39,983 | |
| 9/1/2016 | John W Kozarich | Director | Sell | 1,666 | $105.40 | $175,596.40 | 40,783 | |
| 8/1/2016 | John W Kozarich | Director | Sell | 1,000 | $137.57 | $137,570.00 | 41,783 | |
| 7/1/2016 | John W Kozarich | Director | Sell | 1,000 | $121.40 | $121,400.00 | 42,883 | |
| 6/1/2016 | John W Kozarich | Director | Sell | 1,000 | $117.42 | $117,420.00 | 43,361 | |
| 5/18/2016 | Melanie J Herman | Director | Sell | 334 | $120.50 | $40,247.00 | 3,297 | |
| 5/6/2016 | Jason Aryeh | Director | Sell | 25,000 | $119.20 | $2,980,000.00 | 58,337 | |
| 5/2/2016 | John W Kozarich | Director | Sell | 1,000 | $121.57 | $121,570.00 | 43,911 | |
| 4/6/2016 | John W Kozarich | Director | Sell | 5,000 | $115.00 | $575,000.00 | 44,711 | |
| 3/17/2016 | Matthew W Foehr | COO | Sell | 6,400 | $96.70 | $618,880.00 | 83,062 | |
| 3/8/2016 | Jason Aryeh | Director | Sell | 6,129 | $101.18 | $620,132.22 | 58,337 | |
| 3/7/2016 | John L Higgins | CEO | Sell | 10,833 | $102.47 | $1,110,057.51 | 120,220 | |
| 1/20/2016 | John W. Kozarich | Director | Sell | 1,666 | $94.94 | $158,170.04 | 49,711 | |
| 11/11/2015 | Melanie J. Herman | Director | Sell | 7,719 | $101.00 | $779,619.00 | 3,151 | |
| 8/17/2015 | David M Knott | Director | Sell | 4,000 | $95.98 | $383,920.00 | | |
| 8/13/2015 | David M Knott | Director | Sell | 49,800 | $96.26 | $4,793,748.00 | | |
| 7/10/2015 | Charles S Berkman | VP | Sell | 14,067 | $99.14 | $1,394,602.38 | | |
| 6/26/2015 | Matthew W Foehr | COO | Sell | 12,500 | $100.97 | $1,262,125.00 | | |
| 6/22/2015 | Matthew W Foehr | COO | Sell | 23,046 | $96.45 | $2,222,786.70 | | |
| 6/10/2015 | Melanie J Herman | CFO | Sell | 4,125 | $93.50 | $385,687.50 | | |
| 6/9/2015 | John L Higgins | CEO | Sell | 10,000 | $92.88 | $928,800.00 | | |
| 6/4/2015 | Jason Aryeh | Director | Sell | 1,640 | $92.68 | $151,995.20 | | |
| 5/20/2015 | Jason Aryeh | Director | Sell | 9,240 | $87.34 | $807,021.60 | | |
| 5/14/2015 | Nishan M Desilva | CFO | Sell | 68,363 | $83.91 | $5,736,339.33 | | |
| 3/19/2015 | Sunil Patel | Director | Sell | 4,591 | $74.42 | $341,662.22 | | |
| 2/10/2015 | Nishan M Desilva | VP | Sell | 2,300 | $56.34 | $129,582.00 | | |
| 10/15/2014 | John W Kozarich | Director | Buy | 2,000 | $45.68 | $91,360.00 | | |
| 10/9/2014 | Jason Aryeh | Director | Buy | 11,000 | $42.99 | $472,890.00 | | |
| 8/15/2014 | John L Higgins | CEO | Buy | 1,000 | $54.97 | $54,970.00 | | |
| 6/9/2014 | Melanie J Herman | Director | Sell | 1,100 | $69.68 | $76,648.00 | | |
| 5/27/2014 | Charles S Berkman | VP | Sell | 7,166 | $66.90 | $479,405.40 | | |
| 3/25/2014 | Bvf Partners P/Il | Insider | Sell | 78,226 | $70.09 | $5,482,860.34 | | |
| 3/19/2014 | Todd Davis | Director | Sell | 7,500 | $79.57 | $596,775.00 | 32,536 | |
| 3/18/2014 | John Lamattina | Director | Sell | 5,000 | $78.83 | $394,150.00 | 21,356 | |
| 2/20/2014 | Bvf Partners P/Il | major shareholder | Sell | 422,900 | $73.81 | $31,214,249.00 | | |
| 2/18/2014 | David Knott | Director | Sell | 41,900 | $75.71 | $3,172,249.00 | 63,743 | |
| 2/14/2014 | Jason Aryeh | Director | Sell | 40,320 | $76.44 | $3,082,060.80 | 31,243 | |
| 2/14/2014 | Matthew Foehr | COO | Sell | 22,500 | $79.54 | $1,789,650.00 | 53,457 | |
| 12/12/2013 | Matthew Foehr | COO | Sell | 6,000 | $53.40 | $320,400.00 | 44,929 | |
| 12/6/2013 | John Sharp | CFO | Sell | 6,000 | $56.08 | $336,480.00 | 17,667 | |
| 10/18/2013 | John L Higgins | CEO | Sell | 10,000 | $55.00 | $550,000.00 | | |
| 9/23/2013 | Bvf Partners P/Il | major shareholder | Sell | 359,023 | $44.50 | $15,976,523.50 | | |
| 9/12/2013 | David Knott | Director | Sell | 160,000 | $46.78 | $7,484,800.00 | 63,743 | |
| 8/30/2013 | Charles Berkman | VP | Sell | 28,323 | $47.54 | $1,346,475.42 | 26,936 | |
| 8/16/2013 | Charles Berkman | VP | Sell | 14,583 | $42.63 | $621,673.29 | 17,928 | |
| 8/16/2013 | John Higgins | CEO | Sell | 10,000 | $42.85 | $428,500.00 | 116,581 | |
| 8/16/2013 | John Sharp | CFO | Sell | 7,500 | $42.75 | $320,625.00 | 24,166 | |
| 6/28/2013 | Matthew W Foehr | COO | Buy | 1,059 | $17.36 | $18,384.24 | | |
| 5/10/2013 | Charles S Berkman | VP | Sell | 4,000 | $26.66 | $106,640.00 | | |
| 1/23/2013 | Bvf Partners L P/Il | Major Shareholder | Buy | 39,600 | $19.78 | $783,288.00 | | |
| 12/14/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 5,386 | $18.63 | $100,341.18 | | |
| 12/6/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 50,100 | $17.94 | $898,794.00 | | |
| 12/5/2012 | John L Higgins | CEO | Buy | 2,000 | $18.03 | $36,060.00 | | |
| 10/31/2012 | Bvf Partners L P/Il | Major Shareholder | Buy | 16,591 | $15.19 | $252,017.29 | | |
| 8/29/2012 | David M Knott | Director | Buy | 2,743 | $16.36 | $44,875.48 | | |
(Data available from 1/1/2013 forward)
Ligand Pharmaceuticals (NASDAQ LGND) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Ligand Pharmaceuticals (LGND) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 8:14 AM |
 | Ligand Pharma (LGND) Prices Offering of $650 Million of Convertible Senior Notes
www.streetinsider.com - May 19 at 8:39 AM |
 | What You Must Know About Ligand Pharmaceuticals Incorporated’s (NASDAQ:LGND) Financial Strength
finance.yahoo.com - May 18 at 5:23 PM |
| Ligand Prices Offering of $650 Million of Convertible Senior Notes
finance.yahoo.com - May 18 at 9:20 AM |
| Ligand Pharmaceuticals (LGND) Expected to Announce Quarterly Sales of $38.96 Million
www.americanbankingnews.com - May 18 at 1:59 AM |
 | Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
www.benzinga.com - May 17 at 5:38 PM |
 | Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
www.nasdaq.com - May 17 at 5:38 PM |
 | BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes
www.reuters.com - May 17 at 5:38 PM |
| Ligand Pharma (LGND) Proposed Offering of $650M of Convertible Senior Notes
www.streetinsider.com - May 17 at 8:56 AM |
| Today's Research Reports on Trending Tickers: OPKO Health and Ligand Pharmaceuticals
finance.yahoo.com - May 17 at 8:56 AM |
| Ligand Pharmaceuticals (LGND) Expected to Announce Earnings of $0.71 Per Share
www.americanbankingnews.com - May 16 at 9:16 PM |
 | Ligand Pharma readies $650M convertible debt offering
seekingalpha.com - May 16 at 5:09 PM |
| Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
finance.yahoo.com - May 16 at 5:09 PM |
| Ligand Pharmaceuticals (LGND) CEO Sells $2,232,527.85 in Stock
www.americanbankingnews.com - May 15 at 7:17 PM |
| Edited Transcript of LGND earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 12 at 9:08 AM |
| Ligand Pharmaceuticals (LGND) Insider Sells $1,488,722.03 in Stock
www.americanbankingnews.com - May 11 at 7:41 PM |
| Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
finance.yahoo.com - May 11 at 5:21 PM |
| Ligand Pharmaceuticals (LGND) Upgraded to A- by TheStreet
www.americanbankingnews.com - May 11 at 3:53 PM |
| Ligand to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 11 at 9:13 AM |
 | Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
www.msn.com - May 10 at 5:24 PM |
| Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View
finance.yahoo.com - May 9 at 5:08 PM |
| Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View
finance.yahoo.com - May 9 at 5:08 PM |
| HC Wainwright Reaffirms Buy Rating for Ligand Pharmaceuticals (LGND)
www.americanbankingnews.com - May 9 at 3:12 PM |
| Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q1 2018 Results - Earnings Call
seekingalpha.com - May 9 at 8:49 AM |
| Ligand Pharma (LGND) Tops Q1 EPS by 40c
www.streetinsider.com - May 9 at 8:49 AM |
| Ligand Pharmaceuticals (LGND) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 7:50 PM |
| Ligand Pharmaceuticals (LGND) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 6:52 PM |
| Ligand Pharmaceuticals Inc Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 8 at 5:09 PM |
| Ligand: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:09 PM |
| Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
finance.yahoo.com - May 7 at 5:14 PM |
| Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
finance.yahoo.com - May 7 at 8:44 AM |
| AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View
finance.yahoo.com - May 4 at 5:03 PM |
| Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1
finance.yahoo.com - May 4 at 5:03 PM |
| Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO
www.msn.com - May 3 at 5:01 PM |
| Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
finance.yahoo.com - May 3 at 5:01 PM |
| What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)
finance.yahoo.com - May 3 at 8:41 AM |
| Ligand Pharmaceuticals (LGND) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 3 at 12:39 AM |
| What Lies Ahead for Ligand (LGND) This Earnings Season?
finance.yahoo.com - May 2 at 5:11 PM |
| Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 4:40 AM |
| Brokerages Expect Ligand Pharmaceuticals (LGND) Will Post Quarterly Sales of $32.34 Million
www.americanbankingnews.com - May 1 at 3:50 AM |
 | Ligand Pharmaceuticals Incorporated (LGND) Sees Hammer Chart Pattern: Time to Buy?
www.zacks.com - April 30 at 8:51 AM |
| Analysts Expect Ligand Pharmaceuticals (LGND) Will Announce Earnings of $1.28 Per Share
www.americanbankingnews.com - April 29 at 9:16 AM |
| Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
finance.yahoo.com - April 27 at 4:58 PM |
| Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
finance.yahoo.com - April 27 at 4:58 PM |
| Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
finance.yahoo.com - April 26 at 4:59 PM |
| Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
finance.yahoo.com - April 26 at 4:59 PM |
| Ligand Pharmaceuticals (LGND) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - April 26 at 2:04 PM |
| Ligand Pharmaceuticals (LGND) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 8:50 AM |
| Ligand to Report First Quarter 2018 Results on May 8th
finance.yahoo.com - April 24 at 5:15 PM |
| Calithera's Kidney Cancer Candidate Gets Fast Track Status
www.zacks.com - April 19 at 5:14 PM |
Ligand Pharmaceuticals (NASDAQ:LGND) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ligand Pharmaceuticals (NASDAQ:LGND) Income Statement, Balance Sheet and Cash Flow Statement
Ligand Pharmaceuticals (NASDAQ LGND) Stock Chart for Thursday, May, 24, 2018
Loading chart…
